Vivakor, Inc. (VIVK): Nasdaq/NYSE listing notice — Vivakor receives Nasdaq bid price deficiency notice; issues $6.625M convertible note

Vivakor, Inc.

Nasdaq deficiency letter for bid price <$1.00 for 30 days; 180-day cure period ends Sept 15, 2025.
Issued $6.625M junior secured convertible note to J.J. Astor & Co.; net $5M received after fees.
Note payable in 42 weekly installments of $157,739; may be paid in shares at 20% discount to market.
Issued 250,000 commitment shares as additional consideration; registration rights agreement filed.
Existing senior debt ~$48.5M; convertible note is junior secured with mandatory prepayment from equity receipts.

item 1.01 item 3.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vivakor, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 18, 2025, the Company received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company can regain compliance with the minimum bid price requirement at any time within the 180 calendar day period following receipt of the Nasdaq notice, or until Septembe

View on SEC.gov

Browse all listing & compliance notices →

Vivakor, Inc. filing history →

Source: SEC EDGAR

accession 0001829126-25-001988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.